Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians

Liese Barbier1, Yannick Vandenplas1, Steven Simoens1, Paul Declerck1, Arnold G. Vulto1,2*† and Isabelle Huys1†

Abstract

Background: With the approval of biosimilars for subcutaneously administered products, such as adalimumab, etanercept and insulin, biosimilars become increasingly available in ambulatory care. Little is known about the knowledge and attitudes of healthcare providers who are in charge of dispensing and prescribing biosimilars in this context. This study aims to assess the knowledge and perception about biosimilars among community pharmacists and physicians.

Methods: Belgian community pharmacists (n = 177) and physicians (n = 30) were surveyed on their knowledge, experience with dispensing/prescribing biologicals including biosimilars, perception regarding interchangeability, switching and substitution and informational and educational needs. Descriptive and statistical analyses were performed.

Results: Only 32% of community pharmacists and 52% of physicians had yet dispensed/prescribed a biosimilar. Approximately 35% of community pharmacists felt insufficiently trained to counsel patients with biosimilar therapy, which was significantly higher compared to their self-assessed competence to counsel patients with biological therapy in general (p = 0.023). Community pharmacists experienced questions about similarity between reference products and biosimilars (47%) and their interchangeability (42%). Over 40% of physicians found patient uncertainty about efficacy and safety challenging when prescribing biosimilars. A similar proportion of physicians would only prescribe a biosimilar in indications for which the biosimilar has been tested clinically. The majority of pharmacists (58%) was in favor of substitution of biologicals, on the condition that the prescriber would be contacted. Also over 40% of physicians was open to this approach in case of substitution. Educational support, budget for additional staff and transparency about savings were considered suitable stimuli to incentivize biosimilar use. The need for information about biologicals including biosimilars was nearly unanimous among community pharmacists. Also 67% of physicians requested more information. Both community pharmacists and physicians preferred to be informed by their respective professional associations.

Conclusions: This study showed a substantial need for targeted educational measures to increase the knowledge and confidence about both biological medicines in general and biosimilars in particular among Belgian community pharmacists and physicians.
pharmacists and physicians. The results may inform educational and policy measures to stimulate biosimilar use in ambulatory care.

Keywords: Biosimilar, Biologic, Community pharmacist, Physician, Healthcare professional, Primary care, Ambulatory care, Interchangeability, Pharmacy substitution

Background

Biological medicines have substantially altered the treatment pathway of several chronic and life-threatening diseases, positively affecting the life of many patients. The use and success of biological medicines comes, however, at a considerable cost because of their generally high prices. The arrival of expensive innovative medicines increasingly challenges healthcare systems to find avenues to optimize spending while ensuring access to these therapies for their patients [1].

Following the expiry of exclusivity of a reference biological medicine, biosimilar alternatives can become available and introduce price competition in the market. As defined by the European Medicines Agency (EMA), a biosimilar is “a biological medicinal product that contains a version of the active substance of an already authorized original biological medicinal product (reference medicinal product)” [2]. Competition created by biosimilar entry has shown to result in decreased treatment costs and in some cases to facilitate patient access to biological therapies [3]. Moreover, savings derived from biosimilar competition may contribute to the financing of expensive innovative therapies [4].

In 2005, Europe took the lead in developing a tailored legal and regulatory pathway for the evaluation and approval of biosimilars [2, 5]. Fifteen years after the first biosimilar approval in Europe, over 60 biosimilars are approved for 16 distinct biological products across multiple therapeutic areas, including chronic inflammatory diseases and oncology [6].

Biosimilar development follows a different drug development paradigm compared to that of a new medicinal product. For a biosimilar, developers do not need to demonstrate de novo efficacy or safety, as these properties are well known and established for the reference product. Instead, biosimilars need to demonstrate high similarity in efficacy, safety and quality in relation to the reference product. Because of the inherent variability of biological medicines and the complexity of manufacturing, small differences may be present between a reference product and a biosimilar (which nota bene may also be the case between batches of the same biological). Biosimilars are thus highly similar but not identical versions of the reference product. In biosimilar development, it needs to be demonstrated that these small differences are not meaningful in terms of clinical outcomes. For this, regulators evaluate the totality of evidence gathered to demonstrate biosimilarity which finds its basis in an extensive physico-chemical and biological characterization and comparison with the reference product. Biosimilar approval may rely in part on the knowledge of the reference product and is predominately based on comparative analytical and functional data, since this is a much more sensitive approach in detecting potential differences than a clinical study. As such, generally fewer clinical studies need to be carried out for a biosimilar than for the reference product [5, 7, 8].

After the evaluation and approval at European level, biosimilar market entry and implementation is organized by the individual European Member States. Biosimilar uptake varies among Member States, which may be partly explained by differing biosimilar market entry policies. In Belgium, 31 biosimilar products are reimbursed and available on the market [10], but biosimilar uptake is generally low compared to other European Union countries [3, 9–13].

As biosimilars represent a different development and approval paradigm, their acceptance by healthcare providers, patients and policy makers may require a change in mind-set [7]. Multiple studies have assessed the awareness and knowledge about biosimilars among healthcare providers and patients, identifying generally low to moderate levels of knowledge and trust in biosimilars and related concepts [14]. Whereas the knowledge and perceptions of healthcare providers and patients have been assessed in different regions of the world and European countries [14, 15], research with Belgian healthcare providers and patients is rather limited. Early Belgian policy oriented research identified a lack of awareness, a lack of information and concerns about interchangeability among healthcare providers as factors limiting biosimilar adoption in Belgium [16, 17]. In 2017, the results of a survey among 41 Belgian rheumatologists revealed that they have doubts about the safety and efficacy of biosimilars and have concerns about their interchangeability with its reference product [18]. Interchangeable use refers to the possibility of exchanging one medicine for another medicine that is expected to have the same clinical effect. This could mean exchanging a reference product with a biosimilar (or vice versa) or replacing one biosimilar with another. When the prescriber decides to exchange, such practice is termed a “transition” or “switch”. If done at
pharmacy level without consulting the prescriber, such
an exchange is termed “(automatic) substitution” [5].
While switching biological reference products with their
biosimilar or vice versa has become common practice,
substitution of biologicals is largely not allowed or cov-
ered by a legal framework in Europe [19]. Also in Bel-
gium, substitution of biologicals is not allowed [20].

Over previous years, several initiatives with the aim
to increase biosimilar use have been implemented in
Belgium. Policy actions include the establishment of
a biosimilar usage target in hospitals, biosimilar use
monitoring, and the stimulation of tender procedures.
In 2018, a media campaign was launched to provide
information on biosimilars to healthcare providers,
patients and by extent the general public [12, 21–23].
This joint initiative by the Belgian competent authority
and the reimbursement agency included the launch of
a website with biosimilar information, patient leaflets
and radio spots [22, 24]. Most of the above-mentioned
measures focused on biosimilar use in hospitals, as the
first available biosimilars are mainly used in the hospi-
tal in- or out-patient setting. Despite the multitude of
policy initiatives taken, the use of biosimilars in Bel-
gium continues to lag behind. Especially market shares
of biosimilars dispensed in the community pharmacy
are low [13, 25]. With the approval of biosimilars for
high-value subcutaneously administered products
(such as adalimumab and etanercept), biosimilars
become increasingly available outside of the hospital
setting in Belgium.

The arrival of biosimilars in ambulatory care comes
with a distinct set of additional challenges compared
to biosimilar use in the hospital context. The relative
newness of biosimilars in this setting, the limited dif-
fERENCE in list price between reference products and
biosimilars, the lack of incentives for involved health-
care providers and patients to use biosimilars, poss-
sible differences in injection device, and the lack of an
organized mechanism that may drive biosimilar use via
tenders and facilitate switch management, as present
in hospitals, may further complicate biosimilar use. Table 1 shows an overview of available biosimilars in
ambulatory care in Belgium. An overview of relevant
terminology used throughout this article is provided in
Additional file 3.

Considering that biosimilars are increasingly avail-
able for a new group of Belgian healthcare providers,
especially community pharmacists and general practi-
tioners, and the criticality of their role in the use of bio-
similars, this study aims to investigate their knowledge

Table 1 Biosimilars available in ambulatory care in Belgium (May 2021) [10]

| INN               | Product type     | Net 2019 expenditure [26] | Reference product | Biosimilar      | Reimbursement date biosimilar** [27] |
|-------------------|-----------------|---------------------------|-------------------|-----------------|-------------------------------------|
| Adalimumab*       | TNF inhibitor    | 95,207,248                | Humira®           | Amgevita®       | 1/10/2018                           |
|                   |                 |                           |                   | Hulio®          | 1/1/2019                            |
|                   |                 |                           |                   | Hyrimoz®        | 1/1/2019                            |
|                   |                 |                           |                   | Idacio®         | 1/10/2019                           |
|                   |                 |                           |                   | Imraldi®        | 1/10/2018                           |
| Enoxaparin*       | LMWH            | 22,446,229                | Clexane®          | Ghemaxan®       | 1/1/2021                            |
| Etanercept*       | TNF inhibitor    | 45,197,777                | Entrel®           | Beneplali®      | 1/09/2016                           |
|                   |                 |                           |                   | Erelz®          | 1/7/2019                            |
|                   |                 |                           |                   | Nespero®        | 1/2/2021                            |
| Filgrastim        | G-CSF           | NPA                       | Neupogen®         | Accofi®         | 1/6/2016                            |
|                   |                 |                           |                   | Nivestim®       | 1/3/2014                            |
|                   |                 |                           |                   | Tevagratst®     | 1/2/2010                            |
| Follitropin alfa  | FSH             | NPA                       | Gonat-F®          | Bemfola®        | NA                                  |
|                   |                 |                           |                   | Ovaleur®        | NA                                  |
| Insulin glargine* | Long-acting insulin analogue | 30,344,794 | Lantus®          | Abasaglar®      | 1/6/2016                            |
| Somatropin        | Growth hormone  | NPA                       | Genotropin®       | Omnitrope®      | 1/4/2014                            |

G-CSF granulocyte colony-stimulating factor, INN international non-proprietary name, LMWH low molecular weight heparin, NPA not publicly available, NA not applicable, non-reimbursed medicines, FSH follicle-stimulating hormone, TNF tumor necrosis factor

* Biologicals that are part of the top 25 medicine expenditures in the Belgian ambulatory sector. Insulin aspart is also part of this list (reference product: NovoRapid®,
net 2019 expenditure: 22,229,748) and has an authorized biosimilar: Insulin aspart Sanofi®. Insulin aspart Sanofi® has, however, not (yet) been launched in Belgium [26]. Also the EU-approved biosimilars of teriparatide (reference product: Forsteo®, EU-approved biosimilars: Movymia®, Terrosa®, Livogiva®, Qutavina®) and insulin lispro (reference product: Humalog®, EU-approved biosimilar: Insulin Lispro Sanofi®) are not (yet) available on the market in Belgium [6, 26, 28]

** Reimbursement date of the first available product package
and perception regarding biological medicines including biosimilars.

**Methods**

**Survey design and data collection**

Two sets of surveys, one for community pharmacists and one for physicians, were developed. The surveys were designed based on a review of the literature and consisted of five main parts: (i) participant characteristics, including experience with dispensing/prescribing biologicals in general and biosimilars in particular; (ii) knowledge about biosimilars; (iii) attitudes regarding dispensing/prescribing biologicals in general and biosimilars in particular; (iv) attitudes regarding interchangeability, switching, substitution, and (v) informational and educational needs. In the physician survey, a sixth category was included: (vi) attitudes regarding drivers and incentives for prescribing biosimilars. Questions were tailored to the particular stakeholder group. Participants received definitions on biological medicines, biosimilars, interchangeability, switching and substitution where appropriate. The surveys consisted predominately of closed multiple-choice questions. For some questions, multiple answers could be selected. The survey also included Likert scale questions, in which participants were asked to indicate their level of agreement with a proposed statement. The survey was tested in and adapted based on three pilot surveys. Both surveys were made available in Dutch and French to cater to the two main language regions in Belgium. The web-surveys were created using the online survey platform, SurveyMonkey®. The survey launched in November 2018 and closed in March 2019. Ethics approval was granted by the Research Ethics Committee UZ/KU Leuven (MP006667, Belgium).

**Participants**

Two healthcare provider groups were targeted to participate: (i) community pharmacists and (ii) general practitioners and physician specialists who prescribe subcutaneous biologicals that are dispensed via the community pharmacy, for which an EMA evaluated and European Commission (EC) approved biosimilar alternative is available on the Belgian market (i.e., endocrinologists, rheumatologists, gastro-enterologists and dermatologists).

Healthcare providers across Belgium were invited to participate. Medical and pharmacy professional organizations on a national and regional level were asked to disseminate the survey among their members. The invitation to participate and the link to the online survey was subsequently included in newsletters and professional websites or social media pages of participating professional associations. In addition to this, community pharmacists involved in the training program of KU Leuven Master students Pharmaceutical Care received an invitation to participate. Additionally, participants were identified via the network of the research group.

**Data analysis**

Results were analyzed descriptively for the overall participant group per stakeholder category. In the results section, relative numbers are presented as percentages and the considered sample size, which varied throughout the survey due to the logic applied in the survey questions and participant dropout, is included. Additional inferential statistics to test for differences between certain groups of interest (i.e., experienced and less experienced pharmacists and questions of interest (i.e., self-assessed competence in dispensing biologicals in general vs biosimilars in particular) were performed using Statistica software (Version 14). The Fisher exact test was used to compare proportions of categorical data. This test was chosen since the retrieved samples were small for certain questions. All tests were performed on a significance level of 5% ($\alpha = 0.05$), meaning $p$-values of lower than 0.05 were considered significant.

**Results**

To contextualize the results regarding the knowledge and perception of healthcare providers about prescribing or dispensing biosimilars, the surveys also enquired about their knowledge and perception regarding biological medicines in general.

**Community pharmacists**

**Participant characteristics**

In total, 177 Belgian community pharmacists participated. All regions in Belgium were represented, although most participants worked in Flanders (86%, $n = 153/177$). Responses were gathered across different age groups and most participants were female (69%, $n = 123/177$) (Table 2). Of the 177 participating community pharmacists, 115 completed the survey in full.

**Experience with dispensing biologicals including biosimilars**

Most pharmacists indicated to have experience with dispensing biological medicines (84%, $n = 148/177$). Not surprisingly, almost all had experience with dispensing Tumor Necrosis Factor (TNF)-alpha inhibitors (95%, $n = 119/125$) and hormones such as insulin, growth hormone, and follicitropin-alpha (94%, $n = 118/125$), as both product classes are dispensed in the community pharmacy in Belgium (Additional file 2: Table S1).

A smaller portion of pharmacists had experience with dispensing biosimilars (32%, $n = 45/139$). Noteworthy, an
identical number did not know whether they had yet dispensed a biosimilar or not. The majority who indicated to have dispensed a biosimilar, had experience with dispensing biosimilars of hormones (67%, \( n = 24/36 \)) and TNF-alpha inhibitors (64%, \( n = 23/36 \)) (Additional file 2: Table S2).

Knowledge about biosimilars
To evaluate the knowledge of pharmacists, respondents were asked about the accuracy of a few statements on biosimilar medicines (Additional file 1: Figure S1). The majority (67%, \( n = 95/142 \)) correctly indicated a biosimilar to be highly similar in efficacy, safety, and quality to the reference product. Noteworthy, 18% (\( n = 25/142 \)) had heard about biosimilars, but did not really know what the term means.

To test possible differences in knowledge about biosimilars between more recently graduated and more senior pharmacists, results of respondents with more versus less than 20 years of pharmacy experience were compared statistically (Additional file 2: Table S3). For none of the statements a statistically significant difference was found between less and more experienced pharmacists.

Attitudes about dispensing biologicals including biosimilars
When examining the self-assessed competency of pharmacists to dispense biologicals in general and biosimilars in particular (Fig. 1), over one-third felt only comfortable with dispensing less complex biologicals (43%, \( n = 54/125 \)) and biosimilars (33%, \( n = 12/36 \)), such as insulin but not the more complex anti-TNF products. About one-fourth of pharmacists (18%, \( n = 22/125 \)) felt insufficiently trained to dispense and guide patients with their biological treatment. For biosimilars, this portion was larger (36%, \( n = 13/36 \)). Pharmacists felt significantly less trained to dispense and guide patients with a biosimilar than a biological medicine in general (\( p = 0.023 \)). For all other statements, no statistically significant difference in attitudes between dispensing biologicals in general and biosimilars in particular was found (Additional file 2: Table S4). Also, no significant differences were found in the self-assessed competency to dispense biologicals in general and biosimilars between pharmacists with more versus less than 20 years of experience as community pharmacist. Only when asked if they feel well trained and informed to dispense a biological, a statistically significant difference was found between groups (\( p = 0.032 \)) (Additional file 2: Tables S5 and S6).

Only 22% (\( n = 23/103 \)) agreed or fully agreed with the statement that they felt sufficiently trained to lead the dispensing discussion with the patient when dispensing biologicals (Additional file 1: Figure S2). For biosimilars in particular, this proportion was even lower (13%, \( n = 4/30 \)). While the majority felt neutral about this statement, both for biologicals in general (46%, \( n = 47/103 \)) and biosimilars (57%, \( n = 17 \)), about 30% of pharmacists disagreed with the statement for both.

When asked which challenges they experience when dispensing biologicals, pharmacists selected questions about interchangeability (51%, \( n = 64/125 \)), the method of administration (42%, \( n = 53/125 \)), lack of education and training (39%, \( n = 49/125 \)), and immunogenicity (34%, \( n = 43/125 \)). Only four pharmacists (3%) indicated to experience no challenges when dispensing biologicals (Fig. 2a).

With biosimilars, almost half of the pharmacists indicated to experience questions about the similarity of the biosimilar with its reference product (47%, \( n = 17/36 \)) as challenging when dispensing. Over one-third also indicated to experience questions about interchangeability

| Characteristics | Community pharmacists | \( n = \) |
|-----------------|-----------------------|---------|
| Sex             |                       |         |
| Female          | 123                   | 69      |
| Male            | 54                    | 31      |
| Age             |                       |         |
| < 30 years      | 44                    | 25      |
| > 30 years–45 years | 56                 | 32      |
| > 45 years–60 years | 72                | 41      |
| > 60 years      | 5                     | 3       |
| Years of experience as community pharmacist | | |
| < 2 years       | 18                    | 10      |
| 2–5 years       | 28                    | 16      |
| 6–10 years      | 23                    | 13      |
| 11–20 years     | 30                    | 17      |
| 21–30 years     | 59                    | 33      |
| > 30 years      | 19                    | 11      |
| Working region  |                       |         |
| Brussels        | 10                    | 6       |
| Flanders        | 153                   | 86      |
| Wallonia        | 14                    | 8       |
| Working environment |                  |         |
| Community pharmacy | 177              | 100     |
| Professional pharmacist group | 10  | 6     |
| University      | 1                     | 1       |
| Other           | 3                     | 2       |

Percentages are rounded to the nearest integer
\( N \): number
between the biosimilar and its reference product (42%, \( n = 15/36 \)), a lack of education and training (39%, \( n = 14/36 \)), a lack of accessible and useful information sources (36%, \( n = 13/36 \)), and a general lack of information (36%, \( n = 13/36 \)) here (Fig. 2b).

The majority of pharmacists (73%, \( n = 88/120 \)) considered a counselling treatment conversation needed when a patient starts a treatment with a self-injectable biological. Approximately 50% considered it needed when a patient switches from a self-injectable reference biological product to a biosimilar or vice versa (Additional file 1: Figure S3).

**Attitudes about interchangeability, switching, and substitution**

Approximately half of pharmacists (47%, \( n = 60/129 \)) deemed a small molecule medicine to be interchangeable with its generic (Fig. 3). For reference biological and biosimilar medicines this percentage dropped to about one quarter (26%, \( n = 33/129 \)).

About one-third of pharmacists (35%, \( n = 45/129 \)) believed that an authorized biosimilar can be considered interchangeable with its reference product. The majority (60%, \( n = 77/129 \)) believed that additional data are needed to demonstrate interchangeability besides these for marketing authorization (Additional file 1: Figure S4a). Opinions about the interchangeability of two biosimilars of the same reference product differed (Additional file 1: Figure S4b).

Over half of pharmacists (58%, \( n = 72/124 \)) indicated to believe that they should be allowed to substitute the original biological with its biosimilar, after contacting the prescribing physician (Fig. 4). Over a third (34%, \( n = 42/124 \)) believed that automatic substitution could be applied in the future when more experience has been gained with biosimilars, while 26% (\( n = 32/124 \)) thinks automatic substitution can be applied, depending on the complexity of the product. Only 10% (\( n = 13/124 \)) believed that substitution between biological reference and biosimilar medicines should be allowed automatically.

When asked to what extent they agreed with the statement that substitution of biological medicines could be done, after contact with the prescriber, the majority (73%, \( n = 91/124 \)) either agreed or fully agreed (Additional file 1: Figure S5a). Switching from a biological reference product to a biosimilar or vice versa should remain the responsibility of the prescribing physician, according to 66% (\( n = 82/124 \) agreed or fully agreed with the statement) of pharmacists.
Informational and educational needs

Less than half of pharmacists (42%, \( n = 47/113 \)) had followed a training or educational symposium about biologicals in the past. A smaller portion had followed one specifically about biosimilars (22%, \( n = 25/113 \)) (Additional file 2: Tables S1 and S2).

A high need for information about biologicals in general (91%, \( n = 105/115 \)), and biosimilars in particular (96%, \( n = 110/115 \)) was expressed (Fig. 5). Almost all (95%, \( n = 107/115 \)) indicated they would like to follow a training about biological including biosimilar medicines (Additional file 1: Figure S6a). Pharmacists expressed interest in almost any type of the suggested topics (Additional file 1: Figure S6b). When asked by which organization they prefer to be informed, national or regional professional organizations were ranked first.
Fig. 3 Community pharmacist and physician views on interchangeability. Interchangeability: interchangeability refers to the possibility of exchanging one medicine for another medicine that is expected to have the same clinical effect. This could mean replacing a reference product with a biosimilar (or vice versa) or replacing one biosimilar with another. N number, RP reference product.

Fig. 4 Questions about (automatic) substitution to community pharmacists and physicians. Automatic substitution: the pharmacist dispenses one medicine instead of another equivalent and interchangeable medicine at pharmacy level without consulting the prescriber. N number, RP reference product.
by more than half (51%, \(n = 59/115\)) (Additional file 1: Figure S6c).

**Physicians**

**Participant characteristics**

In total, 30 physicians participated in this study. Most worked in Flanders (80%, \(n = 24/30\)), while a minority worked in Wallonia (20%, \(n = 6/30\)). Physicians were specialized in a variety of therapeutic domains, including rheumatology (33%, \(n = 10/30\)), dermatology (17%, \(n = 5/30\)) and general practice (13%, \(n = 4/30\)) (Table 3).

**Experience with prescribing biologicals including biosimilars**

The majority of physicians (77%, \(n = 23/30\)) had experience with prescribing biological medicines. A few (10%, \(n = 3/30\)) did not know if they had prescribed a biological medicine (Additional file 2: Table S7).

Over half of physicians (52%, \(n = 14/27\)) had prescribed a biosimilar. Seven percent indicated to have not prescribed a biosimilar, but to follow a patient under treatment with a biosimilar (\(n = 2/27\)). The majority (67%, \(n = 16/24\)) did not have experience with switching a patient under treatment with a reference product to a biosimilar (Additional file 2: Table S8).

**Knowledge about biosimilars**

Most physicians recognized that biosimilars are similar in efficacy, safety, and quality with respect to their reference medicine (63%, \(n = 17/27\)). About ten percent had heard about biosimilars, but did not know what the term exactly means (11%, \(n = 3/27\)) (Additional file 1: Figure S1).

**Attitudes about prescribing biologicals including biosimilars**

When asked about challenges that they experience when prescribing biologicals in general, most physicians indicated to have questions about the interchangeability of biological medicines (39%, \(n = 9/23\)). The price of biological medicines (35%, \(n = 8/23\)) and questions about their

![Information needs about biologicals (in general) and biosimilars (in particular)](image-url)
immunogenicity (35%, n = 8/23) were also recognized as challenging (Fig. 2a).

When prescribing biosimilars, physicians indicated to experience questions about the similarity of biosimilars with their reference product (44%, n = 7/16), uncertainties of patients about the efficacy and safety of biosimilars (44%, n = 7/16), and questions about interchangeability between biosimilars and their reference product (38%, n = 6/16) (Fig. 2b) as challenges.

### Attitudes about interchangeability, switching, and substitution

Half of physicians believed generic medicines and their original product are interchangeable (50%, n = 12/24). This proportion was smaller for biosimilar and reference products (42%, n = 10/24) (Fig. 3). The majority was of the opinion that additional data are needed to demonstrate that a biosimilar is interchangeable with its reference product upon authorization (63%, n = 15/24) (Additional file 1: Figure S4a).

Most physicians were not in favor of substitution in an automatic way (55%, n = 12/22). About 40% believed that the pharmacist should be allowed to substitute after contact with the prescriber (41%, n = 9/22) (Fig. 4).

The majority of physicians (77%) disagreed or fully disagreed with the statement that substitution of a biological reference product with a biosimilar could be done by the general practitioner after contact with the initiating prescriber. Surprisingly, the percentage of physicians disagreeing was lower (45%, n = 10/22) when asked if they agreed this could be done by the pharmacist, after contact with the prescriber. Regarding switching, 36% of physicians disagreed or fully disagreed with the statement that insufficient data are available about switching between biological reference products and biosimilars (n = 8/22), while 32% was neutral and 32% agreed with the statement (n = 7/22). (Additional file 1: Figure S5b).

### Informational and educational needs

About 70% (n = 15/21) of physicians indicated to have followed a training or symposium about biologicals in general, and over half (52%, n = 11/21) specifically about biosimilars. (Additional file 2: Tables S7 and S8).

The majority indicated a need for more information both about (the prescription and use of) biologicals in general, and biosimilars in particular (67%, n = 14/21) (Fig. 5). When asked by which organization they would like to be informed, the national or regional professional physician association was ranked first, followed by a European professional physician association (Additional file 1: Figure S6d). When asked which organization would be suited to draft guidance about biosimilar use, also the national or regional professional physician association was ranked first. (Additional file 1: Figure S6e).

### Attitudes about drivers and incentives for prescribing biosimilars

When asked for which reasons they would prescribe a biosimilar, the majority of physicians mentioned savings as reason (71%, n = 17/24). Confidence in the evaluation of biosimilars by the EMA (42%, n = 10/24), the fact that the biosimilar is similar compared to the reference product (42%, n = 10/24) and a potential increase in patient

---

**Table 3 Physicians: participants’ characteristics**

| Characteristics                      | Physicians | n  | %  |
|--------------------------------------|------------|----|----|
| **Sex**                              |            |    |    |
| Female                               | 17         | 57 |    |
| Male                                 | 13         | 43 |    |
| **Age**                              |            |    |    |
| < 30 years                           | 3          | 10 |    |
| > 30 years – 45 years                | 14         | 47 |    |
| > 45 years – 60 years                | 9          | 30 |    |
| > 60 years                           | 4          | 13 |    |
| **Years of experience as physician** |            |    |    |
| 0 – 5 years                          | 4          | 13 |    |
| 6 – 10 years                         | 4          | 13 |    |
| 11 – 20 years                        | 11         | 37 |    |
| 21 – 30 years                        | 5          | 17 |    |
| > 30 years                           | 6          | 20 |    |
| **What is your function?**           |            |    |    |
| Rheumatologist                       | 10         | 30 |    |
| Dermatologist                        | 5          | 17 |    |
| Gastro-enterologist                  | 2          | 7  |    |
| Endocrinologist                      | 1          | 3  |    |
| General practitioner                 | 4          | 13 |    |
| Representative medical association    | 1          | 3  |    |
| Other                                | 7          | 23 |    |
| **Working region**                   |            |    |    |
| Brussels                             | 0          | 0  |    |
| Flanders                             | 24         | 80 |    |
| Wallonia                             | 6          | 20 |    |
| **Working environment**              |            |    |    |
| Private practice                     | 12         | 40 |    |
| University hospital                  | 5          | 17 |    |
| General hospital                     | 15         | 50 |    |
| Professional medical association     | 1          | 3  |    |
| University                           | 1          | 3  |    |
| Other                                | 1          | 3  |    |

Percentages are rounded to the nearest integer

*N*: number

---
access to biological therapies (25%, \(n=6/24\)) were also selected (Fig. 6a). When asked for which patient they would prescribe a biosimilar, 42% (\(n=10/24\)) would only prescribe the biosimilar if it was clinically tested for the specific indication of their patient or only for bio-naïve patients (21%, \(n=5/24\)) (Fig. 6b). When asked about reasons not to prescribe biosimilars, 42% (\(n=10/24\)) selected the argument that the product is less clinically tested compared to the reference product, uncertainty of their patient (33%, \(n=8/24\)), and a lack of knowledge about the biosimilar concept and its evaluation (29%, \(n=7/24\)) (Additional file 1: Figure S7).

The majority of physicians recognized the need for some kind of incentive (55%, \(n=12/22\)) to stimulate biosimilar prescription in the ambulatory setting (Additional file 1: Figure S8a). When asked what kind of incentive is expected, information about biosimilars by regulatory authorities, transparency about the realized savings derived from biosimilar market entry, and additional budget for staff to support biosimilar implementation were most frequently indicated (Additional file 1: Figure
While earlier research largely investigated the biosimilars across varying specialisms and countries showing low to moderate knowledge and trust towards healthcare providers. Including biosimilar medicines for this group of Belgian and education about different aspects about biological that there is a substantial demand for more information tives was clearly expressed. The results of this study show be low. Also for physicians, a need for educational initia -lars among Belgian community pharmacists was noted to

Discussion
Since biosimilar use has been predominately a hospital matter in previous years, earlier research in the domain of stakeholder knowledge about biosimilar medicines generally focussed on the knowledge and perception of hospital pharmacists and physician specialists [14]. With the approval of biosimilars for subcutaneously adminis-tered biologicals (such as adalimumab, etanercept and insulin), biosimilars are finding their way to the com-unity pharmacy in Belgium.

In view of the loss of exclusivities of different biologicals with high (therapeutic) value in the ambulatory care setting and the subsequent emergence of biosimilars, this study quantitatively assessed the knowledge and percep-tions of Belgian community pharmacists and physicians about biological including biosimilar medicines in this particular setting.

A clear need for active educational and informational measures
The level of knowledge and understanding about biosimi-lars among Belgian community pharmacists was noted to be low. Also for physicians, a need for educational initia-tives was clearly expressed. The results of this study show that there is a substantial demand for more information and education about different aspects about biological including biosimilar medicines for this group of Belgian healthcare providers.

These findings are consistent with previous research on healthcare provider perceptions about biosimilars, showing low to moderate knowledge and trust towards biosimilars across varying specialisms and countries [14, 15]. While earlier research largely investigated the perspective of healthcare professionals active in the hospital context, a French web-based survey included also the perspective of community pharmacists in their study. Their 2017 survey results showed that about half of community pharmacist survey participants were “not at all” informed about biosimilars, compared to less than one fifth of participating hospital pharmacists [29]. Even though experience with biosimilars may have grown in the ambulatory care setting over the past few years, the results of this current Belgian websurvey indicate that the self-assessed knowledge among community pharmacists about biosimilars is still limited in Belgium.

A survey conducted among Irish general practitioners in 2017 showed that 60% of participants were unable to define a biosimilar or had never heard of the term [30]. A survey among Belgian rheumatologists in 2016, pointed at information gaps and doubts about biosimilar medi-cines. In particular, concerns about the interchangeabil-ity of biological reference products with biosimilars were found [18]. A general lack of familiarity and trust in bio-similar medicines among Belgian physicians was already observed in 2013 [16, 17]. The findings of this study show that physicians’ uncertainty about biosimilars may have not been sufficiently addressed over the past few years.

Moreover, and more surprisingly, this study indicates that community pharmacists and physicians not only face challenges with dispensing or prescribing biosimi-lars but also with biological medicines in general. This statement is supported by the statistical analysis, where nearly no significant differences were found between the self-assessed competences between dispensing biological medicines in general and biosimilar medicines in particu-lar among community pharmacists.

It is essential that physicians and community pharma-cists are well trained to make treatment decisions and counsel patients regarding biological, including biosimi-lar, therapies. Although the biosimilar drug development and regulatory assessment paradigm originates from 2005 and the first biosimilar approval dates from 15 years ago, physicians still ask for clinical studies and pharma-cists have questions about similarity and interchange-ability concepts. As biosimilars are relatively recently available in ambulatory care in Belgium and their market shares remain low, general practitioners and community pharmacists may have been only confronted to a limited extent with biosimilars in clinical practice. Misunder-standings about biosimilar concepts may also stem from a lack of knowledge about biological medicines in general [14]. Nonetheless, physicians and community pharma-cists have the responsibility to prescribe/dispense these medicines in an informed and knowledgeable manner, and adequately counsel patients with their treatment. Healthcare providers are expected to keep up with develop-ments in pharmaceutical therapies that enter clinical practice. University curricula should prepare physicians and pharmacists with up-to-date education and continu-ous education should provide support with lifelong learning during their professional career.

The results of this study ask for an examination of the existing education and outreach on biological medi-cines and biosimilars for Belgian healthcare providers. Whereas earlier research suggested that information lacks [17], informational material on biosimilars is now abundantly available. This suggest that the available
informational material does not effectively reach the physician and pharmacist [14].

An important responsibility lies with the Belgian professional associations to disseminate objective information about biosimilars, and include biosimilar medicines in the continuing education of physicians and pharmacists. The emphasis should be on organizing (mandatory) educational sessions in the framework of lifelong learning, rather than making information passively available. Professional associations and policy makers should collaborate to facilitate a coherent stream of information and develop targeted educational measures to reach healthcare providers maximally. This may benefit from a pro-active and centrally coordinated approach from the Belgian national medicines agency and the Ministry of Social Affairs and Health.

In addition to the importance of permanent education courses to continuously update knowledge and insights of healthcare providers on emerging and evolving topics, the university curricula for future healthcare providers warrant a closer look. A follow-up study investigated the knowledge of Belgian medicine and pharmacy students about biosimilars including biosimilars. Only low to moderate percentages of master students (ranging from 2 to 42%) appear to feel well prepared to work with biosimilars in general and biosimilars in particular in the future [31, 32]. Compared to master students, medicine and pharmaceutical care, master students drug development seem to be more informed [31, 32]. This survey also showed no statistical difference in terms of knowledge about biosimilars between more recently graduated and more senior community pharmacists. Based on an examination of the absence of biological including biosimilar topics in the learning objectives of the pharmacists’ curriculum, it should be considered to expand training on this [31, 32]. University education committees should appraise the courses within the Master’s degrees regarding biological including biosimilar medicines and expand and update content where needed to prepare future healthcare providers with the necessary knowledge and competencies to prescribe/ dispense these medicines [31].

Substitution of biological medicines

Whereas the marketing authorization of biosimilars is based on the recommendation of the EMA and the decision of the EC, decisions on interchangeability and substitution are made at the Member State level [5]. Similarly to most European countries, pharmacy-level substitution is not allowed for biological medicines in Belgium [20]. In this study, 58% of community pharmacists indicated to be in favor of introducing substitution for biological medicines, albeit after contacting the prescriber. Also 41% of physicians seemed to be in favor of substitution by the community pharmacist, if done with the prescriber’s approval.

Substitution could be a potential strategy to stimulate biosimilar usage in ambulatory care. Since biosimilars have proven to be equally effective and safe as their reference product when they enter the market, substitution has become an organizational or political challenge rather than a scientific one [33]. For example, in France and the US, pharmacist-led substitution for biologicals is legislatively possible [15, 19, 34]. Some other European countries have new legislation planned to allow pharmacist-led substitution for (certain) biologicals [19, 35]. Before this could be explored in the Belgian context, the demand for more information about biological including biosimilar medicines should be met to ensure that involved healthcare providers are well trained to counsel patients regarding biosimilar use and manage such an exchange. An earlier study among Finnish healthcare providers has pointed out several issues, and ways to solve them, regarding the implementation of substitution for biological medicines [34]. Similar to the results of this study, specific educational requirements for all stakeholders involved in the substitution process were underlined as a condition [34]. Community pharmacists and pharmacy staff should be educated and trained to counsel patients including device training. Substitution may also facilitate stock management as it limits the number of expensive biological medicines that must be stocked in the community pharmacy [34].

The role and design of healthcare provider incentives

Besides the knowledge of healthcare providers, other factors may influence the adoption of biosimilars in clinical practice. Next to healthcare providers’ uncertainty and questions regarding biosimilars, low biosimilar use may be explained by the fact that physicians identify no or insufficient benefits to prescribe biosimilars and change their patients in the ambulatory context. Whereas in the hospital setting the use of biosimilars is determined to a large extent by tender mechanisms, no such driver exists in the ambulatory care setting. As the difference in the list price between originator biologicals and biosimilars is generally limited in Belgium [10], physicians may not recognize direct benefits from prescribing a biosimilar. As a considerable proportion of patients treated with biosimilars in the Belgian ambulatory setting are initiated in the physician’s private practice, incentive schemes outside of hospital-level incentives may be required.

The majority of physicians in this survey confirmed the need for prescriber incentives to support biosimilar usage in the ambulatory context. This finding is consistent with previous papers also pointing out the need for tangible incentives for healthcare providers [33, 36].
Following the emergence of biosimilars in the ambulatory care setting, a pilot financial incentive was introduced in 2019 by the Belgian national health insurer linked to the prescription of etanercept and adalimumab biosimilars [37]. The incentive has been discontinued because of its limited success [37]. The current study reveals that prescriber incentives should not necessarily be monetary in nature, as participants ranked informational and educational support as first preferred incentive. When implementing an incentive, it should aim to improve patient care rather than to provide a financial benefit at the level of the individual physician [33, 36]. Budget to remunerate additional staff to support the implementation of biosimilars could serve as a tangible method to incentivize prescribers.

In France such a gain sharing incentive was launched in 2018, as part of their national strategy aiming to achieve 80% biosimilar uptake by 2022 [38]. For biologicals such as adalimumab and etanercept, the initiation of treatment in France is done at the hospital, after which the initiated product is continued in the ambulatory setting [38]. The initiation in the hospital thus influences the subsequent use in the ambulatory setting. Therefore this incentive targeted the hospitals by rewarding them with 20% of the price difference between the originator biological and biosimilar for every insulin glargine, etanercept and adalimumab biosimilar prescribed in the hospital and dispensed in the community pharmacy or for every renewed prescription in the ambulatory setting resulting from the initiation in the hospital [38]. Preliminary results showed a positive effect on biosimilar market shares [39, 40]. Similarly in Ireland, the introduction of a prescribing incentive in the form of a gain-share of €500 per patient initiated or switched to a best-value adalimumab and etanercept was reported to have contributed significantly to an increase in biosimilar use [41].

In addition to a gain sharing incentive, the results presented here indicate that efforts should be made to report transparently about the generated savings from biosimilar competition and how they are used.

**Study strengths and limitations**

This study was the first to examine the level of knowledge and perception of Belgian community pharmacists about biologicals including biosimilars. The relatively large sample size (a sample size of 177 participants allows to report for the population of 9200 Belgian community pharmacists with a confidence level of 95% and error margin of 7.3%), representative distribution of the sex (70% female in both the general Belgian community pharmacist population and survey sample) and fair distribution of age groups among participating pharmacists ensure that these results are indicative for the larger population of Belgian community pharmacists [42–44].

Limitations to the survey include the fact that mainly pharmacists and physicians working in Flanders participated, and the limited sample of participating physicians. Because participants were mainly recruited via professional organizations, a response rate could not be calculated. In addition, one could argue that pharmacists and physicians that showed interest—and participated—in this survey might have a higher level of knowledge about biosimilars than the overall healthcare provider population in Belgium. Moreover, earlier research showed that the flow of information and the knowledge about biosimilars may be higher among Flemish physicians compared with Wallonian physicians [45]. The results of this survey might therefore be even an overestimation of the actual level of awareness on biosimilars, which was already reported to be low in this study.

**Future perspectives**

Initiatives and incentives targeted at pharmacists and physicians should play a central role in future policy making to support biosimilar usage in ambulatory care. As drivers appear to be lacking for biosimilar use in ambulatory care in Belgium, the exploration of policies and incentives in the ambulatory care context is becoming more pertinent. A continuing low use of biosimilars may deter companies to launch future biosimilars on the Belgian market. In Belgium, no insulin lispro biosimilar has been launched so far. Also, Mylan’s insulin glargine biosimilar (Semglee®) is not marketed in Belgium [10]. Belgian policymakers should work closely together with healthcare providers to create incentives tailored to their needs, in order to create a balanced climate for off-patent biological and biosimilar medicines.

In addition to policy actions, the university curricula should be fit for purpose to prepare physicians and pharmacists for their prescribing and dispensing responsibility of best-value biologicals (both reference biologicals and biosimilars). Education should include elements on cost-effective medicine use.

Besides the perspective of Belgian healthcare providers, the views of Belgian patients should be assessed. The perspectives of ambulatory care patients are currently being investigated in a subsequent study commissioned by the Belgian national health insurer [46]. The results of these two studies can inform the development of new educational initiatives to stimulate biosimilar adoption in clinical practice, tailored to the needs of both Belgian healthcare providers and patients.
Conclusions
This study shows that Belgian community pharmacists and physicians have considerable uncertainties with prescribing and dispensing biological medicines in general and biosimilars in particular. It appears that healthcare provider knowledge gaps about biosimilars have not been sufficiently addressed over previous years. Targeted educational measures that actively reach Belgian community pharmacists and physicians are required to reduce the information gap. Equally, policy interventions to stimulate the use of biosimilar medicines will be needed to ensure that Belgium captures their societal benefits over the longer term. The results of this study can inform the design of necessary educational and policy measures to support biosimilar use in ambulatory care in Belgium.

Abbreviations
EMEA: European Medicines Agency; EC: European Commission; TNF: Tumor necrosis factor.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40545-021-00330-x.

Additional file 1: Figure S1. Familiarity with and knowledge about biosimilars among community pharmacists and physicians. Figure S2. Additional question on the self-assessed competence of community pharmacists to dispense biologicals (in general) and biosimilars (in particular). Figure S3. Opinion of community pharmacists about the organisation of a counselling treatment conversation for patient biosimilar use. Figure S4. Additional questions posed to community pharmacists and physicians regarding interchangeability. Figure S5. Additional questions posed to community pharmacists and physicians regarding substitution. Figure S6. Additional questions posed to community pharmacists and physicians regarding information and training needs. Figure S7. Reasons why physicians would not prescribe a biosimilar. Figure S8. Questions about the need for incentives to stimulate biosimilar prescription in the ambulatory setting.

Additional file 2: Table S1. Community pharmacists: participants’ experience with biologicals in general. Table S2. Community pharmacists: participants’ experience with biosimilars. Table S3. Statistical analysis—testing for differences between experienced and more recently graduated pharmacists in terms of knowledge about biosimilars. Table S4. Statistical analysis—testing for differences between the self-assessed competences of pharmacists in dispensing biologicals in general versus biosimilars in particular. Table S5. Statistical analysis—testing for differences between the self-assessed competences of pharmacists in dispensing biologicals in general versus biosimilars in particular. Table S6. Statistical analysis—testing for differences between the self-assessed competences of pharmacists in dispensing biologicals in general versus biosimilars in particular. Table S7. Physicians: participants’ experience with biologicals in general. Table S8. Physicians: participants’ experience with biosimilars.

Additional file 3: Supplementary Box 1 Key terminology.

Acknowledgements
The authors would like to thank all survey participants for their insights. The authors also thank A. Jans for creating the web-version of the survey and her help with its dissemination. We also thank B. Counezon for her support with translating the survey in French, and J. Wuyts, A. Thijs and L. Billen for piloting the survey questions. The authors would also like to acknowledge the following organizations for their support in disseminating the survey in their network: De West-Vlaamse Apothekersvereniging, Groupement Belge de Médecins Spécialistes/Verbond Der Belgische Beroepsverenigingen van Arsten-Specialisten (GBS-VBS), Huisartsenkring Prometheus, Instituut voor permanente studie voor apothekers (IPSAP), Koninklijke Apothekers Vereeniging van Antwerpen (KAVA), Koninklijk Limburgs Apothekers Verbond (KLAV), Koninklijk Oost-Vlaams Apothekersgilde (KOVAG), Office des Pharmacies Coopératives de Belgique (Opahaco), Société Scientifique des Pharmaciens Francophones (SSPF), apotheken De Lindeboom, het Zwaard, Vivantia.

Authors’ contributions
IH, AGV, PD, SS and LB were involved in the development of the study design. LB collected and analyzed the survey data. LB and YV co-wrote the first draft of the manuscript. All authors reviewed the manuscript and added suggestions. All authors read and approved the final manuscript.

Funding
This work is supported by KU Leuven and the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund).

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.

Declarations
Ethics approval and consent to participate
Ethics approval was granted by the Research Ethics Committee UZ/KU Leuven (MP006667, Belgium).

Consent for publication
Not applicable.

Competing interests
IH, SS, PD and AGV are the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund). AGV is involved in consulting, educational work and speaking engagements for a number of companies, i.e., Abbvie, Accord, Amgen, Biogen, EfiA, EGA, Pfizer/ Hospira, Fresenius-Kabi, Mundipharma, Roche, Novartis, Sandzod, Boehringer Ingelheim. SS was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD, and he has participated in advisory board meetings for Amgen, Pfizer and Sandzod. He has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma and Pfizer; and he has had speaking engagements for Amgen, Celltrion and Sandzod. PD participated at advisory board meetings for Abbvie, Amgen, Hospira, and Samsung Bioepis and is on the Speakers’ Bureau of Abbvie, Celltrion, Hospira, Meck Sereno, and Roche. All authors declare that the research was conducted in the absence of any commercial or financial relationship that could be perceived as a potential conflict of interest.

Author details
1Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, Box 521, 3000 Leuven, Belgium. 2Hospital Pharmacy, Erasmus University Medical Center, Box 2040, 3000 CA Rotterdam, The Netherlands.

Received: 3 March 2021   Accepted: 31 May 2021

Published online: 22 June 2021

References
1. Godman B, Bucsis A, Bonanno PV, Oortwijn W, Rothe CC, Ferrario A, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
2. European Medicines Agency. Guideline on similar biological medicinal products. 2014.
3. IQVIA. The impact of biosimilar competition in Europe. 2019.
4. Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in European off—patent bioscience and biosimilar markets: it is not only about price! BioDrugs. 2020;34(2):159–70.

5. European Medicines Agency. Biosimilars in the EU—information guide for healthcare professionals. 2017.

6. European Medicines Agency. Biosimilar medicines. https://www.emepharma.eu/en/medicines/field_ema_web_categories%25a7/field/Human/ema_group_types/ema_medicine/field_ema_med_status_authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosim. Accessed Jan 23 2021.

7. Gonzalez-Quevedo R, Wolff-Holz E, Carr M, Garcia BJ. Biosimilar medicines: why the science matters. Health Policy Technol. 2020;9(2):129–33.

8. Wolff-Holz E, Titso K, Vlemmixs C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621–34.

9. IQVIA. Advancing biosimilar sustainability in Europe—a multi-stakeholder assessment. 2018.

10. BCFI. Gecommentarieerd Geneesmiddelenrepertorium. www.bcfi.be. Accessed 10 May 2021.

11. Simon Kucher & Partners. Payors’ price & market access policies supporting a sustainable biosimilar medicines market. 2016.

12. Beledsel van de minister van Sociale Zaken en Volksgezondheid. Convenant Doenstart voor biosimilair geneesmiddelen in Belgien. 2016.

13. Medeaxes Memorandum. 2019.

14. Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars: part I—improving biosimilar understanding and adoption. BioDrugs. 2020;34:783–96.

15. Sarnola K, Merkoski M, Jyrkkä J, Hämeen-Anttila K. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10:e034183.

16. Lepage-Neffens I, Gerkens V, Vinck I, Pléart J, Hulstaert F, Farfán-Portet P-I. Barriers and opportunities for the uptake of biosimilar medicines in Belgium. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). 2013. KCE Reports 199 D/2013/10.273/13.

17. Dylist P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. PharmacoEconomics. 2014;32:681–91.

18. Van Overbeeke E, De Beleyr B, De Hoon J, Westhovens R, Huys I. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs. 2017;31(5):447–59.

19. Larkin H, Macdonald J, Lumsden R. Pharmacy-mediated substitution of biosimilars—a global survey benchmarking country substitution policies. Generics Biosimilars Initiat J. 2017;6(4):157–64.

20. Federal Agency for Medicines and Health Products. Switch and substitution of biologic medicines: why the science matters. Health Policy Technol. 2020;9(2):129–33.

21. Ministry of Social Affairs and Health. Omzendbrief actieplan biosimilars. 2016.

22. Van Overbeeke E, De Beleyr B, De Hoon J, Westhovens R, Huys I. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs. 2017;31(5):447–59.

23. Larkin H, Macdonald J, Lumsden R. Pharmacy-mediated substitution of biosimilars—a global survey benchmarking country substitution policies. Generics Biosimilars Initiat J. 2017;6(4):157–64.

24. Federal Agency for Medicines and Health Products. Switch and substitution of biologic medicines: why the science matters. Health Policy Technol. 2020;9(2):129–33.

25. IQVIA. The impact of biosimilar competition in Europe. 2020.

26. National Institute for Health and Disability Insurance (RIZIV/INAMI). Infospot—De TOP 25 van de werkzame bestanddeelnissen in de uitgaven in de ambulante sector van de verzekering voor geneeskundige verzorging. 2020.

27. Vandenbulcke B. Knowledge of biological medicines, including biosimilars, among medically trained students in Flanders—Master thesis Pharmaceutical Care KU Leuven. 2020.

28. Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars: part II—improving biosimilar use in clinical practice. BioDrugs. 2020;34:797–808.

29. Tolonen HM, Airaksinen MSA, Ruokoniemi P, Hämenn-Anttila K, Shermock KM, Kurki P. Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative study. BMJ Open. 2019;9:e032892.

30. Barbier L, Mbuaki A, Simoens S, Vulto A, Huys I. PNS151 The role of regulatory guidance and information dissemination for biosimilars—the perspective of healthcare professionals and industry. Value Health. 2019;12(2):S786–7.

31. Moorkens E, Vulto AG, Huys I, Vulto AG. Biosimilars in Belgium: a proposal for a more competitive market. Acta Clin Belg. 2020;May(13):1–12.

32. National Institute for Health and Disability Insurance (RIZIV/INAMI). Biosimilair geneesmiddelen: incentief voor het voorschrijven van biosimilair geneesmiddelen buiten het ziekenhuis. https://www.inami.fgov.be/nl/themas/kost terugbetaling/door ziekenfonds/geneesmidd el-genezheidspunct/geneesmiddel-voorschrijven/Paginas/biosimilai re-geneesmiddelen-buiten-ziekenhuis.aspx. Accessed 26 Nov 2020.

33. CREES (Direction de la recherche, des études, de l’évaluation et des statistiques). Medicamente biosimilaires: l’hopital, premier vecteur de leur diffusion. 2019.

34. Paulsel P, Degрасsart-Théas A, Bocquet F. Impact of French experiment for incentivising etanercept biosimilar use after 10 months. EHJP 2020;7(Suppl 1):A1–232 (SPD-108).

35. Baudard P, Duhamel J, Bourguignon S. PMU53 the incentive financial framework regarding French hospital prescription of biosimilar medicines when delivered in retail pharmacy: impact analysis of article 51 experimentation for 2018. Value Health. 2019;22(November):S717.

36. Duggan B, Barry ASM. Uptake of biosimilars for TNF—a inhibitors adalimumab and etanercept following the best—value biological medicine initiative in Ireland. Int J Clin Pharm. 2021. https://doi.org/10.1007/s11096-021-01243-0.

37. Bartram B, Huys I, Vulto AG, Simoens S, Vulto AG. Biosimilars—a global survey benchmarking country substitution policies. Generics Biosimilars Initiat J. 2017;6(4):157–64.

38. Barbier L, Simoens S, Vulto AG, Huys I. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs. 2017;31(5):447–59.

39. Larkin H, MacDonald J, Lumsden R. Pharmacy-mediated substitution of biosimilars—a global survey benchmarking country substitution policies. Generics Biosimilars Initiat J. 2017;6(4):157–64.

40. Federal Agency for Medicines and Health Products. Switch and substitution of biologic medicines: why the science matters. Health Policy Technol. 2020;9(2):129–33.

41. Minister of Social Affairs and Health. Omzendbrief actieplan biosimilars. 2018.

42. Federal Agency for Medicines and Health Products. Nieuwe campagne eventueel substitutie van biologische geneesmiddelen. Accessed 11 Dec 11 2020.

43. National Institute for Health and Disability Insurance (RIZIV/INAMI). Knowledge of biological medicines, including biosimilars. The role of regulatory guidance and information dissemination for biosimilars—the perspective of healthcare professionals and industry. Value Health. 2019;12(2):S786–7.

44. ABS. Welkom bij uw apotheker. SurveyMonkey. Steekproefcalculator. https://nl.surveymonkey.com/mp/sample-size-calculator/. Accessed 13 Jan 2021.

45. Creative Research Systems. Sample size calculator. https://www.scscale.com/sscalc.htm. Accessed 16 Jan 2021.

46. Everaert M. Market research on the perception, awareness and usage of biosimilars with healthcare professionals—Master in Drug Development Pharmaceutical Care KU Leuven. 2020.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.